Physician profile
Chan M Ma
NPI 1487642120
$38,154.83
in general payments reported to CMS, 2019-2025
44 companies · $4,990 in 2025
The $4,990 reported for 2025 was more than what 93% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $4,316 · 2021: $4,603 · 2022: $4,045 · 2023: $4,058 · 2024: $4,497 · 2025: $4,990.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,348.86 |
| Education | $196.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $7,557.91 | 2019-2025 | Farxiga, Lokelma, Brilinta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,413.62 | 2019-2025 | Jardiance |
| Gilead Sciences, INC. | $4,161.08 | 2019-2025 | Vemlidy, Livdelzi |
| Travere Therapeutics, INC. | $2,100.65 | 2020-2025 | Filspari |
| Bayer Healthcare Pharmaceuticals INC. | $1,756.92 | 2021-2025 | |
| Vifor Pharma, INC. | $1,721.56 | 2019-2025 | Veltassa, Korsuva |
| Amgen INC. | $1,619.94 | 2019-2025 | Tavneos, Krystexxa, Repatha |
| Glaxosmithkline, LLC. | $1,575.08 | 2019-2025 | Benlysta, Trelegy Ellipta |
| Horizon Therapeutics Plc | $1,285.55 | 2019-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $1,240.51 | 2019-2025 | Jynarque, Voyxact |
| Calliditas Therapeutics US INC. | $965.06 | 2022-2025 | Tarpeyo |
| Amarin Pharma, INC. | $951.66 | 2019-2023 | |
| Akebia Therapeutics INC | $803.81 | 2019-2025 | Vafseo, Auryxia |
| Aurinia Pharma U.S., INC. | $718.64 | 2021-2024 | Lupkynis |
| Opko Pharmaceuticals, LLC | $679.07 | 2019-2025 | Rayaldee |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chan Ma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.